文献速递肺外科

SHURUI单孔蛇形臂机器人系统在肺手术中的安全性与有效性:前瞻性单中心研究

Safety and Efficacy of SHURUI Single-Port Serpentine-Arm Robotic Surgery System in Lung Surgery: A Prospective Single-Centre Study.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

本研究前瞻性纳入15例接受机器人肺切除术的患者,评估国产SHURUI单孔蛇形臂机器人系统的安全性与有效性。主要终点为中转开胸率和Clavien-Dindo≥3级器械相关并发症发生率。结果显示所有手术均未中转开胸,中位总手术时间174分钟,无30天死亡,表明该系统用于解剖性肺切除可行且安全性可接受。

要点

  • 15例机器人肺切除术均未中转开胸,1例需辅助孔。
  • 中位总手术时间174分钟,术中失血100 mL,中位住院5天。
  • 无Clavien-Dindo≥3级器械相关并发症,30天内无死亡。

核心结论

  • SHURUI单孔机器人系统用于解剖性肺切除可行,安全性可接受。

研究设计与样本

  • 前瞻性单中心试验纳入15例接受机器人肺切除术的患者。
  • SHURUI系统经第五/第六肋间切口置入,采用双连续体机制的蛇形臂器械。

主要发现

  • 所有手术(8例肺叶切除、5例肺段切除、2例袖状肺叶切除)均未中转开胸,1例需辅助孔。
  • 中位总手术时间174分钟(117-335),建孔时间14分钟(8-30),对接时间4分钟(3-6),控制台时间117分钟(56-233)。
  • 术中失血100 mL(10-300),中位住院时间5天(3-12)。
  • 术后1小时、24小时、72小时数字评分法(NRS)疼痛评分分别为3、3、2。
  • 外科医生满意度中位数95/100;2例轻微并发症(漏气延长、贫血)保守治愈,1例因胸腔积液再入院行胸腔穿刺。

关键数值与推荐

  • 主要终点:中转开胸率和符合Clavien-Dindo≥3级标准的器械相关或可能器械相关手术并发症发生率。
  • 次要终点包括手术时间、失血量、疼痛评分、外科医生满意度、不良事件发生率、输血率、30天再入院率、30天再手术率和30天死亡率。

临床怎么用

  • 国产单孔蛇形臂机器人系统可用于解剖性肺切除,短期安全性和可行性良好。

局限性

  • 单中心、小样本(15例)前瞻性研究,缺乏对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The integration of robot-assisted thoracic surgery (RATS) and uniportal video-assisted thoracic surgery (VATS) is poised to become a key direction for future advancements. The SHURUI single-port (SP) Robotic Surgery System, China's first domestically developed SP endoscopic system, has shown promise in urological and gynaecological surgeries but lacks thoracic application data. This study evaluates its safety and efficacy in anatomical lung resection. METHODS: A prospective single-centre trial enrolled 15 patients undergoing robotic pulmonary resection. The SHURUI system, featuring serpentine-arm instruments with dual continuum mechanisms, was deployed via a fifth/sixth intercostal incision. Primary endpoints included the non-conversion rate and the incidence of device-related or potentially device-related surgical complications meeting Clavien-Dindo grade 3 or higher criteria; secondary endpoints encompassed operative time, blood loss, pain scores, surgeon satisfaction, the incidence of adverse events, transfusion rates, 30-day readmission rates, 30-day reoperation rates, and 30-day mortality. RESULTS: All procedures (8 lobectomies, 5 segmentectomies, and 2 sleeve lobectomies) achieved 100% non-conversion, with one case requiring an auxiliary port. Median total operative time, port creation time, docking time, and console time were 174 minutes (117-335), 14 minutes (8-30), 4 minutes (3-6), and 117 minutes (56-233), respectively. Blood loss was 100 mL (10-300), and the median hospital stay was 5 days (3-12). Postoperative pain scores according to the numerical rating scale (NRS) were 3, 3, and 2 at 1 hour, 24 hours, and 72 hours. Surgeons reported 95/100 median satisfaction. Two minor complications (prolonged air leak, anaemia) resolved conservatively; one readmission for pleural effusion required thoracentesis. No mortality was observed within the 30-day postoperative period. CONCLUSIONS: This study demonstrates the feasibility and acceptable safety of using the SHURUI SP robotic surgery system for anatomical lung resection. CLINICAL REGISTRATION NUMBER: The study protocol was registered at http://www.chictr.org.cn/ (ChiCTR2400084046).

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Li C, Xie Z, Ding C, et al. Safety and Efficacy of SHURUI Single-Port Serpentine-Arm Robotic Surgery System in Lung Surgery: A Prospective Single-Centre Study. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 41172271. doi:10.1093/icvts/ivaf232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。